Concerns Rise Over Betting Impact on Drug Trials and Trust

WHO:

New York Times - Doctors and researchers are expressing concerns regarding the impact of betting on drug trials.

WHAT:

New York Times - There are wagers on whether the Food and Drug Administration (FDA) will make decisions regarding drug approvals this year on platforms like Kalshi and Polymarket.

Drudge Report - Concerns have been raised about betting undermining research integrity and public trust.

WHERE:

New York Times - The betting platforms Kalshi and Polymarket are mentioned as locations where these wagers are placed.

WHY:

New York Times - The primary concern is that these bets could compromise drug development tests and erode public trust in the FDA's decision-making process.

HOW:

New York Times - The betting on FDA decisions is facilitated through online platforms, allowing individuals to place wagers on the outcomes of drug approvals.

(UPDATED July 29, 2026 04:05 UTC)

Doctors and researchers are raising alarms about the potential impact of betting on drug trials, particularly as wagers are being placed on whether the FDA will make drug approval decisions this year on platforms like Kalshi and Polymarket. There are growing concerns that this betting could undermine the integrity of research and erode public trust in the FDA's decision-making process. As individuals place bets online regarding the outcomes of drug approvals, the implications for drug development tests and public confidence in health regulations are becoming increasingly significant.